6FWW

GFP/KKK. A redesigned GFP with improved solubility

6FWW の概要

• エントリーDOI: 10.2210/pdb6fww/pdb
• 分子名称: Green fluorescent protein (2 entities in total)
• 機能のキーワード: protein aggregation, aggregation prediction, protein design, aggrescan 3d, fluorescent protein
• 由来する生物種: Aequorea victoria (Jellyfish)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 29851.56

構造登録者

Varejao, N.,Lascorz, J.,Gil-Garcia, M.,Diaz-Caballero, M.,Navarro, S.,Ventura, S.,Reverter, D. (登録日: 2018-03-07, 公開日: 2018-08-01, 最終更新日: 2024-01-17)

主引用文献

Gil-Garcia, M.,Bano-Polo, M.,Varejao, N.,Jamroz, M.,Kuriata, A.,Diaz-Caballero, M.,Lascorz, J.,Morel, B.,Navarro, S.,Reverter, D.,Kmiecik, S.,Ventura, S.
Combining Structural Aggregation Propensity and Stability Predictions To Redesign Protein Solubility.
Mol. Pharm., 15:3846-3859, 2018

PubMed Abstract: The aggregation propensity of each particular protein seems to be shaped by evolution according to its natural abundance in the cell. The production and downstream processing of recombinant polypeptides implies attaining concentrations that are orders of magnitude above their natural levels, often resulting in their aggregation; a phenomenon that precludes the marketing of many globular proteins for biomedical or biotechnological applications. Therefore, there is a huge interest in methods aimed to increase the proteins solubility above their natural limits. Here, we demonstrate that an updated version of our AGGRESCAN 3D structural aggregation predictor, that now takes into account protein stability, allows for designing mutations at specific positions in the structure that improve the solubility of proteins without compromising their conformation. Using this approach, we have designed a highly soluble variant of the green fluorescent protein and a human single-domain VH antibody displaying significantly reduced aggregation propensity. Overall, our data indicate that the solubility of unrelated proteins can be easily tuned by in silico-designed nondestabilizing amino acid changes at their surfaces.

PubMed: 30036481
DOI: 10.1021/acs.molpharmaceut.8b00341

実験手法

X-RAY DIFFRACTION (1.131 Å)